Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens\u00ae and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX\u2122 as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
Leveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.
MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
Follows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
Collaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
OXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
Theolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
JLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center\u00ae for Life Science \u2013 New York City.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology\r\ncompany harnessing the power of non-coding human genetics to discover first-in-class antibody\r\ntreatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business\r\nOfficer with immediate effect.
![\"\"\n](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio2019s-darkfox-discovery-propels-ena101-the-first-ever-bispecific-t-cell-engager-targeting-a-cancer-specific-dark-antigen-into-ind-enabling-studies/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n